Mate

Manufacturer
Aurora Pharmaceutical, Inc.
Effective date
2023-09-06
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-06-01 02:42:15

Label at a glance#

ProductMate
Active ingredientALTRENOGEST
Label structure8 sections

Dosage and administration

For oral administration. Administer 1 mL MATE per 50 kg bodyweight (equivalent to 0.044 mg altrenogest per kg) daily. 1. Regulation and control of the breeding cycle of mares a. For the induction of ovulatory oestrus or to induce cyclical ovarian activity in mares with some follicle activity early in the breeding season: Administer MATE daily for 10 consecutive days. b. For the suppression of oestrus in normally c...

Storage and handling

Store below 25°C (air conditioning). Protect from light.

Label contents#

Full prescribing information#

DOSAGE FORMS & STRENGTHS SECTION

2.2 mg/mL altrenogest

VETERINARY INDICATIONS SECTION

For regulation and control of the breeding cycle of mares
• To induce ovulatory oestrus early in the breeding season in mares where some follicular activity exists
• For the suppression of oestrus either during prolonged oestrus or in normally cycling mares
• For the control of the ovarian cycle in breeding mares to allow the most efficient use of the stallion

For the maintenance of pregnancy in habitually aborting mares, or mares at risk of early embryonic death or abortion, where progesterone deficiency is thought to be the underlying cause.

CONTRAINDICATIONS SECTION

Read the carton for full instruction

DIRECTIONS FOR USE

Restraints:
DO NOT USE on male animals.

Contraindications:
Contraindicated for use in mares suffering from uterine infections.

Precautions:
Use with caution as unused feed must be destroyed and not given to any other animals.
MATE must be added to the feed immediately prior to consumption and not stored.

Dosage and Administration:

DOSAGE & ADMINISTRATION SECTION

For oral administration.
Administer 1 mL MATE per 50 kg bodyweight (equivalent to 0.044 mg altrenogest per kg) daily.
1. Regulation and control of the breeding cycle of mares
a. For the induction of ovulatory oestrus or to induce cyclical ovarian activity in mares with some follicle activity early in the breeding season: Administer MATE daily for 10 consecutive days.
b. For the suppression of oestrus in normally cycling mares: Administer MATE daily for 15 consecutive days. For the suppression of prolonged oestrus: Administer MATE daily for 10 consecutive days.
c. To control the breeding cycle of mares to allow efficient use of the stallion: Administer MATE daily for 15 consecutive days.
2. For the treatment of habitually aborting mares, or mares at risk of early embryonic death or abortion: Administer MATE daily, from the 2nd or 3rd day after ovulation in the mated or inseminated mare, continuing until day 120 of gestation.

NOTE: Ultrasound scanning to confirm pregnancy is recommended on day 14 or 15 after ovulation. If the mare is not pregnant, it is advised to cease MATE administration and to administer an injection of prostaglandin F2α to destroy any luteal tissue that may be still present, allowing the mare to return to oestrus and be re-mated.

MEAT WITHHOLDING PERIODS (HORSES)

DO NOT USE less than 28 days before slaughter for human consumption.

SAFETY DIRECTIONS

SAFE HANDLING WARNING SECTION

Product is harmful if absorbed by skin contact, inhaled or swallowed. Avoid contact with eyes and skin. Do not inhale. When using the product wear rubber gloves. After use and before eating, drinking or smoking, wash hands, arms and face thoroughly with soap and water. After each day's use, wash gloves. Care should be taken to avoid contact between the solution and women of child bearing age.

FIRST AID INSTRUCTIONS
If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 13 11 26.

ADDITIONAL USER SAFETY INFORMATION
Additional information is listed in the safety data sheet (SDS).

STORAGE

STORAGE AND HANDLING SECTION

Store below 25°C (air conditioning). Protect from light.

SPL UNCLASSIFIED SECTION

Manufactured by:
Aurora Pharmaceutical, Inc.

Distributed by:
South Yarra Pharma Pty Ltd
27-33 Piper Line, East Bendigo VIC 3550
Australia
Call Toll-free: 1800 426 142

APVMA Approval No.: 92068/134364

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PRINCIPAL DISPLAY PANEL - 1000 mL bottle label

IN 50-1715 06/2023

1L Bottle label1L Bottle label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1314617altrenogest 0.22 % Oral SolutionPSN1
1314617altrenogest 2.2 MG/ML Oral SolutionSCD1
1314617altrenogest 0.22 % Oral SolutionSY1

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
51072-119-00Mate1000 mL in 1 BOTTLESOLUTION10001

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
51072-119MATE (ALTRENOGEST) SOLUTION [AURORA PHARMACEUTICAL, INC.]11 package rows20230908_60ed5a69-e07d-404f-9f96-3ff732815711.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
51072-11951072-119-00

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
ALTRENOGEST2U0X0JA2NBACTIB

Source Document#

Source XML

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.